A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis
✍ Scribed by Dennis McGonagle; Andrew Rawstron; Stephen Richards; John Isaacs; Howard Bird; Andrew Jack; Gareth Morgan; Paul Emery
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 488 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Objective:
To examine the safety and efficacy of granulocyte colony-stimulating factor (g-csf) alone for the mobilization of peripheral blood progenitor cells in patients with resistant active rheumatoid arthritis (ra).
Methods:
Five patients with resistant active ra were studied. a dose of 5 microg/kg of g-csf (filgrastim) was given subcutaneously each day for 5 days, and the number of stem cells mobilized into the peripheral blood was assessed by daily cd34 counts. ra disease activity was assessed by standard clinical methods.
Results:
The absolute numbers of peripheral blood cd34+ cells peaked on day 4, with a mean value of 0.025 x 10(9)/liter (range 0.013-0.048 x 10(9)/liter). there was no significant change in disease activity during the study or in the month following therapy.
Conclusion:
Using g-csf alone, cd34+ progenitor peripheral blood cells were mobilized in numbers suitable for leukopheresis. g-csf therapy was well-tolerated in patients with active ra, and was not associated with a flare during treatment or in the month following treatment.